Turning cancer’s immune shield into an immune beacon to transform patient outcomes

Breakthrough therapy designed to reactivate and expand the immune response to unlock deeper, more durable effect in solid tumours

About Us

At Uncover Therapeutics, we are driven by a clear belief: what if the full promise of immunotherapy - the ability of our immune system to cure cancer - could finally be achieved to reach the millions of patients still waiting?

While immunotherapy has transformed outcomes for some, the majority of patients still do not benefit. This remains one of the largest unmet needs in oncology.

We are on a mission to change it.

Our ambition is to advance to clinic a potential first-in-class therapy designed to overcome the key limitations of current immune-oncology therapies. By combining checkpoint inhibition with targeted immune activation - designed to transform cancer’s immune shield into an immune beacon - we aim to unlock deeper and more durable anti-tumour responses.

Supported by compelling preclinical data, the asset is approximately 12-15 months from regulatory submission to enable first-in-human clinical trials in solid tumours.

Uncover’s executive management team combines deep industry expertise with proven execution, bringing decades of experience across both private and public biotech companies. The team has a strong track record in fundraising, M&A, strategic partnerships, and scaling high-growth ventures, as well as advancing innovative therapies through clinical development.

The team also brings deep immuno-oncology expertise, particularly in checkpoint and IL-2 biology. This includes the CSO, who led the discovery of Imfinzi (PD-L1 inhibitor; ~$7bn annual revenue) at AstraZeneca and led development of the underlying therapy at a biotech with >$1bn exit.

The team has worked previously together.